Full metadata record
DC FieldValueLanguage
dc.contributor.authorChu, Che-Shengen_US
dc.contributor.authorLin, Ching-Hengen_US
dc.contributor.authorLan, Tsuo-Hungen_US
dc.contributor.authorChou, Po-Hanen_US
dc.date.accessioned2018-08-21T05:53:16Z-
dc.date.available2018-08-21T05:53:16Z-
dc.date.issued2018-02-01en_US
dc.identifier.issn0165-0327en_US
dc.identifier.urihttp://dx.doi.org/10.1016/j.jad.2017.10.017en_US
dc.identifier.urihttp://hdl.handle.net/11536/144481-
dc.description.abstractBackground: The aim of this study was to investigate whether use of mood stabilizers (MS) is associated with an increased risk of cataract development. Methods: We conducted a nested case-control study using National Health Insurance Research Database in Taiwan. A total of 14,288 patients with bipolar disorder (BD) and schizophrenia were included; 7651 in the cataract group and 6637 in the control group. Based on overall cumulative period of MS (lithium, carbamazepine, valproate, and lamotrigine) treatment, we categorized into following groups: no use, and duration < 1 year, 1 to 2 years, and > 2 years. Conditional logistic regression analysis was used to explore the association between use of MS and risk of cataract development. Results: The risks for cataract development were significantly higher in patients using lithium alone and lithium combined with other MS for more than 2 years (adjusted odd ratio [AOR] = 1.39; 95% CI= 1.01-1.92, p = 0.043 and AOR = 1.44; 95% CI = 1.13-1.85, p = 0.003, respectively) than in non-users. Furthermore, the risks of cataract development increased in those treated with valproic acid combined with other MS (AOR = 1.26; 95% CI= 1.02-1.57, p = 0.035). Finally, no increased risks of cataract development were found in carbamazepine and lamotrigine users. Conclusions: We found increased risks of cataract development in long-term users of lithium, lithium combined with other MS and valproic acid combined with other MS for more than two years among patients with BD and schizophrenia.en_US
dc.language.isoen_USen_US
dc.subjectMood stabilizersen_US
dc.subjectCataracten_US
dc.subjectLithiumen_US
dc.subjectValproateen_US
dc.subjectCarbamazepineen_US
dc.subjectLamotrigineen_US
dc.titleAssociations between use of mood stabilizers and risk of cataract: A population-based nested case-control studyen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.jad.2017.10.017en_US
dc.identifier.journalJOURNAL OF AFFECTIVE DISORDERSen_US
dc.citation.volume227en_US
dc.citation.spage79en_US
dc.citation.epage81en_US
dc.contributor.department光電工程學系zh_TW
dc.contributor.departmentDepartment of Photonicsen_US
dc.identifier.wosnumberWOS:000424323600012en_US
Appears in Collections:Articles